We are proud to announce that Epinostics has been accepted into the 2025/26 cohort of the prestigious London Institute for Healthcare Engineering MedTech Venture Builder—a leading programme designed to accelerate the commercial translation of breakthrough medical technologies into viable, investment-ready ventures.

Epinostics was selected as one of a small group of high-potential MedTech companies from across the UK, recognised for our novel, non-invasive biomarker extraction technology and our ambition to redefine diagnostic sampling through the skin.

Now in its second year, the 12-month MVB programme is the first initiative of its kind in the UK and is jointly delivered by London’s leading academic institutions: Queen Mary University of London, City University of London, and St George’s University of London.

This opportunity will provide Epinostics with tailored executive mentorship and a robust roadmap toward clinical validation and commercial readiness—key steps in delivering our mission to improve diagnostics and empower better health outcomes for all.

We look forward to working alongside experts from the MVB programme and fellow innovators as we take the next major leap in our journey.

Stay tuned for updates as we advance through this exciting phase of development.